2023
DOI: 10.1080/13880209.2023.2191645
|View full text |Cite
|
Sign up to set email alerts
|

Isoalantolactone suppresses gallbladder cancer progression via inhibiting the ERK signalling pathway

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 39 publications
0
3
0
Order By: Relevance
“…The MAPK family plays an important role in regulating the proliferation, differentiation, transformation, apoptosis, and metabolism of malignant tumours 23 , 24 . MAPK signalling is also involved in the occurrence and development of a variety of cancers, indicating its important role in tumour biological processes such as cancer cell proliferation, apoptosis, and differentiation 25 , 26 . The extracellular regulated protein kinase (ERK1/2) family was the first classic MAPK signal transduction pathway to be discovered, and includes Ras, RAF, and MAPK.…”
Section: Discussionmentioning
confidence: 99%
“…The MAPK family plays an important role in regulating the proliferation, differentiation, transformation, apoptosis, and metabolism of malignant tumours 23 , 24 . MAPK signalling is also involved in the occurrence and development of a variety of cancers, indicating its important role in tumour biological processes such as cancer cell proliferation, apoptosis, and differentiation 25 , 26 . The extracellular regulated protein kinase (ERK1/2) family was the first classic MAPK signal transduction pathway to be discovered, and includes Ras, RAF, and MAPK.…”
Section: Discussionmentioning
confidence: 99%
“…We also studied the possible mechanisms of their action using in vitro and in silico molecular screening methods. Thus, to date, the therapeutic potential of isoalantolactone has been convincingly demonstrated in the treatment of bladder [36] and endometrial cancer [37], colorectal carcinoma [38], liver cancer [39], breast cancer [40], etc. [41,42], due to its influence on a wide range of signaling pathways and pathological cascades that play a critical role in the progression of malignant neoplasms.…”
Section: Introductionmentioning
confidence: 99%
“…The ability of dehydrocoslactone to suppress cancer progression by inhibiting migration [47], proliferation, epithelial-mesynchemic transition [48], sub-G1 cell cycle arrest, DNA damage, and loss of mitochondrial membrane potential [49] has been widely described. Thus, to date, the therapeutic potential of isoalantolactone has been convincingly demonstrated in the treatment of bladder [36] and endometrial cancer [37], colorectal carcinoma [38], liver cancer [39], breast cancer [40], etc. [41,42], due to its influence on a wide range of signaling pathways and pathological cascades that play a critical role in the progression of malignant neoplasms.…”
Section: Introductionmentioning
confidence: 99%